InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Cyclerion Therapeutics, Inc.

CYCN Clue Score43
United States Fiscal year ends December CIK 0001755237
Alert on the numbers Alert on insider trades

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2018Operating income−115.3Net income−115.3Fiscal year 2019Revenue4.5Operating income−125.0Net income−123.0Fiscal year 2020Revenue2.3 −49.1%Operating income−81.3Net income−77.8Fiscal year 2021Revenue3.9 +71.7%Operating income−55.2Net income−51.6EPS, diluted−1.32Fiscal year 2022Revenue0.3 −92.5%Operating income−18.5Net income−44.1EPS, diluted−20.28Fiscal year 2023Revenue0.0 −100.0%Operating income−13.0Net income−5.3EPS, diluted−2.25Fiscal year 2024Revenue2.0Operating income−3.6Net income−3.1EPS, diluted−1.21Fiscal year 2025Revenue2.1 +3.7%Operating income−5.0Net income−3.5EPS, diluted−1.11
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a 4.5 2.3 3.9 0.3 0.0 2.0 2.1
Growth −49.1% +71.7% −92.5% −100.0% +3.7%
Operating income −115.3 −125.0 −81.3 −55.2 −18.5 −13.0 −3.6 −5.0
Net income −115.3 −123.0 −77.8 −51.6 −44.1 −5.3 −3.1 −3.5
Growth
EPS, diluted n/a n/a n/a −1.32 −20.28 −2.25 −1.21 −1.11

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2018Fiscal year 2019Operating margin−2,774.3%Net margin−2,729.3%Free cash flow margin−2,420.7%Fiscal year 2020Operating margin−3,539.4%Net margin−3,388.6%Free cash flow margin−3,223.6%Fiscal year 2021Operating margin−1,400.2%Net margin−1,310.2%Free cash flow margin−926.5%Fiscal year 2022Operating margin−6,242.4%Net margin−14,841.1%Free cash flow margin−13,673.7%Fiscal year 2023Fiscal year 2024Operating margin−181.4%Net margin−152.9%Fiscal year 2025Operating margin−239.8%Net margin−170.1%
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a −2,774.3% −3,539.4% −1,400.2% −6,242.4% n/a −181.4% −239.8%
Net margin n/a −2,729.3% −3,388.6% −1,310.2% −14,841.1% n/a −152.9% −170.1%
Free cash flow margin n/a −2,420.7% −3,223.6% −926.5% −13,673.7% n/a n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2018Operating cash flow−97.5Capital expenditure−3.4Free cash flow−100.9Fiscal year 2019Operating cash flow−102.2Capital expenditure−6.9Free cash flow−109.1Fiscal year 2020Operating cash flow−72.5Capital expenditure−1.5Free cash flow−74.0Fiscal year 2021Operating cash flow−36.5Capital expenditure−0.0Free cash flow−36.5Fiscal year 2022Operating cash flow−40.6Capital expenditure0.0Free cash flow−40.6Fiscal year 2023Operating cash flow−21.2Fiscal year 2024Operating cash flow−4.3Fiscal year 2025Operating cash flow−3.3
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −97.5 −102.2 −72.5 −36.5 −40.6 −21.2 −4.3 −3.3
Capital expenditure −3.4 −6.9 −1.5 −0.0 0.0 n/a n/a n/a
Free cash flow −100.9 −109.1 −74.0 −36.5 −40.6 n/a n/a n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2018Cash0.0Shareholders’ equity−10.4Fiscal year 2019Cash94.9Shareholders’ equity97.7Fiscal year 2020Cash54.4Shareholders’ equity59.5Fiscal year 2021Cash54.0Shareholders’ equity48.2Fiscal year 2022Cash13.4Shareholders’ equity10.5Fiscal year 2023Cash7.6Shareholders’ equity11.3Fiscal year 2024Cash3.2Shareholders’ equity8.9Fiscal year 2025Cash3.2Shareholders’ equity9.1
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 0.0 94.9 54.4 54.0 13.4 7.6 3.2 3.2
Shareholders’ equity −10.4 97.7 59.5 48.2 10.5 11.3 8.9 9.1

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022† 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a 4.5 2.3 3.9 0.3 0.0 2.0 2.1
Growth −49.1% +71.7% −92.5% −100.0% +3.7%
87.7 95.1 56.4 37.6 6.0 1.5 0.3 1.0
27.5 34.4 28.8 20.6 12.9 8.1 5.3 6.1
−115.3 −125.0 −81.3 −55.2 −18.5 −13.0 −3.6 −5.0
Growth
−115.3 −122.4 −122.4 −51.6 −44.1 −5.3 −3.1 −3.5
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
−115.3 −123.0 −77.8 −51.6 −44.1 −5.3 −3.1 −3.5
Growth
Per share
n/a n/a n/a −1.32 −20.28 −2.25 −1.21 −1.11
n/a n/a n/a −1.32 −20.28 −2.25 −1.21 −1.11
Growth
n/a n/a n/a 39.1 2.2 2.3 2.5 3.2
n/a n/a n/a 39.1 2.2 2.3 2.5 3.2
Growth −94.4% +7.6% +7.7% +26.3%

† The diluted share count jumps at 2022, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue shrank 2.0% a year over five years.
  • Operating margin is up 3,299.6 points on five years ago, at -239.8%.
  • A net loss in 8 of 8 years on file.